Table 1.

Baseline characteristics of subjects

PlaceboSulindacEtodolac
(n = 58)(n = 60)(n = 61)
Age, (mean ± SD), y64.0 ± 9.965.8 ± 10.263.1 ± 9.7
Sex (M/F)36/2236/2437/26
Colorectal cancer in parent no. (%)8 (13.8)8 (13.3)10 (16.4)
Current smoker, no. (%)11 (19.0)12 (20.0)11 (18.0)
History of diabetes, no. (%)a 5 (8.6)6 (10.0)5 (8.2)
History of hyperlipidemia, no. (%)b 14 (24.1)15 (25.0)16 (26.2)
History of hypertension, no. (%)c 18 (31.0)20 (33.3)18 (29.5)
Findings at baseline CS
 No. of polyps, median (interquartile range)1.0 (0.5–2.0)1.0 (0.0–2.0)1.0 (0.0–2.0)
 No. of adenomas, median (interquartile range)1.0 (0.0–2.0)1.0 (0.0–2.0)1.0 (0.0–2.0)
Polypectomy/polyp-free subjects48/1050/1050/11
  • aHistory of diabetes was defined as use of antidiabetic medication or participant report of clinically diagnosed diabetes.

  • bHistory of hyperlipidemia was defined as use of cholesterol-lowering medication or participant report of clinically diagnosed hyperlipidemina.

  • cHistory of hypertension was defined as use of antihypertensive medication or participant report of clinically diagnosed high blood pressure.